How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis

International Journal of Tuberculosis and Lung Disease

Volumn 2, Issue 1, 1998, Pages 10-15

  Mitchison, D A ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Compliance; Drug resistance; Fourth drug; Rifampicin mono resistance

Indexed keywords

ISONIAZID; RIFAMPICIN; STREPTOMYCIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; COMBINATION CHEMOTHERAPY; HUMAN; NOTE; PATIENT COMPLIANCE; PRIORITY JOURNAL; TUBERCULOSIS;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIBIOTICS, ANTITUBERCULAR; ANTITUBERCULAR AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MICROBIAL; ETHAMBUTOL; HIV SEROPOSITIVITY; HUMANS; ISONIAZID; MUTATION; MYCOBACTERIUM TUBERCULOSIS; PATIENT COMPLIANCE; PYRAZINAMIDE; RECURRENCE; RIFAMPIN; STREPTOMYCIN; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 0031886212     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (24)

1. Drug-resistant tuberculosis: laboratory issues. Vareldzis B P, Grosser J, de Kantor I, Crofton J, Laszlo A, Felten M, Raviglione M C, Kochi A. Tubercle Lung Dis 1994; 75: 1-7.
2. Jindani A, Aber V R, Edwards E A, Mitchison D A. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis 1980; 121: 939-949.
3. Botha F J H, Sirgel F A, Parkin D P, van de Wal B W, Donald P R, Mitchison D A. Early bactericidal activity of ethambutol, pyrazinamide and the fixed combination of isoniazid, rifampicin and pyrazinamide (Rifater) in patients with pulmonary tuberculosis. S Afr Med J 1996; 86: 155-158.
4. Donald P R, Sirgel F A, Botha F J, et al. The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis. Am J Respir Crit Care Med 1997; 156: 895-900.
5. Mitchison D A. Basic mechanisms of chemotherapy. Chest 1980; 76S: 771-781.
6. Lipsitch M, Levin B R. Population dynamics of tuberculosis treatment: mathematical models of the roles of non-compliance and bacterial heterogeneity in the evolution of drug resistance. Int J Tuberc Lung Dis. In press.
7. Kreiss B. Resistance and survival of tubercle bacilli during antibacterial medication (in French). Masson, Paris, 1966: 19.
8. Verbist L, Gyselen A. Antituberculosis activity of rifampin in vitro and in vivo and the concentrations attained in human blood. Am Rev Respir Dis 1968; 98: 923-932.
9. Canetti G, le Litzin M, Porven G, Rise N, Grumbach F. Some comparative aspects of rifampicin and isoniazid. Tubercle 1968; 49: 367-376.
10. Mitchison D A. The action of antituberculosis drugs in short-course chemotherapy. Tubercle 1985; 66: 219-225.
11. Mitchison D A, Dickinson J M. Laboratory aspects of intermittent drug therapy. Postgrad Med J 1971; 47: 737-741.
12. Tuberculosis Chemotherapy Centre, Madras. A controlled comparison of a twice-weekly and three once-weekly regimens in the initial treatment of pulmonary tuberculosis. Bull World Health Organ 1970; 43: 143-206.
13. Kenyan/Zambian/British MRC. Controlled clinical trial of levamisole in short-course chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis 1989; 140: 990-995.
14. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British MRC. A controlled clinical comparison of 6 and 8 months of antituberculosis chemotherapy in the treatment of patients with silicotuberculosis in Hong Kong. Am Rev Respir Dis 1991; 143: 262-267.
15. Hong Kong Chest Service/British Medical Research Council. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, 3 × weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isomazid, rifampin, and pyrazinamide. Am Rev Respir Dis 1991; 143: 700-706.
16. Singapore Tuberculosis Service/British Medical Research Council. Assessment of a daily combined preparation of isoniazid, rifampin and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis. Am Rev Respir Dis 1991; 143: 707-712.
17. Santha T, Nazareth O, Krishnamurthy M S, et al. Treatment of pulmonary tuberculosis with short course chemotherapy in South lndia-5 year follow up. Tubercle 1989; 70: 229-234.
18. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. A controlled trial of 3-month, 4-month, and 6-month regimens of chemotherapy for sputum-smear-negative pulmonary tuberculosis. Am Rev Respir Dis 1989; 139: 871-876.
19. Singapore Tuberculosis Service/British Medical Research Council. Five-year follow-up of a clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 1988; 137: 1147-1150.
20. Hong Kong Chest Service/British Medical Research Council. Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis 1987; 136: 1339-1342.
21. East and Central African/British Medical Research Council (Fifth Collaborative Study). Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis: Final report. Tubercle 1986; 67: 5-15.
22. Fox W. The problem of self-administration of drugs; with particular reference to pulmonary tuberculosis. Tubercle 1958; 39: 269-274.
23. Telenti A, Philipp W, Sreevatsan S, et al. The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol. Nature Med 1997; 3(5): 567-570.
24. Lutfey M, Della-Latta P, Kapur V, et al. Independent origin of mono-rifampin-resistant Mycobacterium tuberculosis in patients with AIDS. Am J Respir Crit Care Med 1996; 153: 837-840.